Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Trial Profile

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2019

At a glance

  • Drugs Copanlisib (Primary)
  • Indications Anaplastic large cell lymphoma; B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms CHRONOS-1
  • Sponsors Bayer
  • Most Recent Events

    • 04 Jun 2019 Results of long-term follow-up of patients with relapsed or refractory follicular lymphoma, treated with copanlisibpresented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 29 May 2019 According to a Bayer media release, the company announced that based on the results of this study, U.S. FDA has granted a Breakthrough Therapy Designation for Aliqopa or the treatment of adult patients with relapsed marginal zone lymphoma (MZL) who have received at least two prior therapies.
    • 13 May 2019 According to a Bayer media release, data from this study will be presented in the upcoming 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019, taking place May 31 to June 4 in Chicago, Illinois (USA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top